APTAMERS and the state of the technology.



The Ontario Genomics Institute (OGI) and NeoVentures Biotechnology Inc.(www.neoventures.ca) are hosting a one hour web conference/webinar about APTAMERS and the state of the technology. NeoVentures has been the first company globally to commercialize aptamer based diagnostics.

With an aptamer-based diagnostic platform there is no need for the maintenance of recombinant cell lines, and antibody production schedules. Aptamers can be chemically synthesized at a commercial scale within a week enabling true on-demand inventory control.

The webinar will cover:

  • Introduction to aptamers
  • Strengths and weaknesses relative to antibodies
  • Aptamer identification
  • Considerations for aptamer based diagnostics
  • Intellectual property landscape
  • NeoVentures services

The presentation will be led by Dr. Greg Penner, President & CEO. The webinar will be appropriate for all levels of research investigators that are interested in learning how aptamer based diagnostic applications can compete directly with antibodies in commercial products.

Please be sure to provide your name, title, institution and valid email address so that we can send you an email with webinar details and instructions.

1. First Name:


2. Last Name:


3. E-mail Address:


4. Role (ie. professor, postdoc, technician, etc):


5. Institution/Company:

Page 1 of 1